Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. Michaloglou C, et al. Nature. 2005 Aug 4;436(7051):720-4. doi: 10.1038/nature03890. Nature. 2005. PMID: 16079850 Free article.
The essence of senescence.
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. Kuilman T, et al. Among authors: michaloglou c. Genes Dev. 2010 Nov 15;24(22):2463-79. doi: 10.1101/gad.1971610. Genes Dev. 2010. PMID: 21078816 Free PMC article. Review.
BRAF(E600) in benign and malignant human tumours.
Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. Michaloglou C, et al. Oncogene. 2008 Feb 7;27(7):877-95. doi: 10.1038/sj.onc.1210704. Epub 2007 Aug 27. Oncogene. 2008. PMID: 17724477 Review.
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C, Crafter C, Siersbaek R, Delpuech O, Curwen JO, Carnevalli LS, Staniszewska AD, Polanska UM, Cheraghchi-Bashi A, Lawson M, Chernukhin I, McEwen R, Carroll JS, Cosulich SC. Michaloglou C, et al. Mol Cancer Ther. 2018 May;17(5):908-920. doi: 10.1158/1535-7163.MCT-17-0537. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483206 Free PMC article.
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. Staniszewska AD, et al. Among authors: michaloglou c. Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022. Oncoimmunology. 2022. PMID: 35756843 Free PMC article.
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer.
Bagal SK, Astles PC, Diène C, Argyrou A, Crafter C, Cassar DJ, Fallan C, Hock A, Jones T, Moreau K, Lamont GM, Lamont S, Michaloglou C, Packer MJ, Pike A, Ramos-Montoya A, Scott JS, Shaw J, Shologu Z. Bagal SK, et al. Among authors: michaloglou c. J Med Chem. 2024 Jul 25;67(14):11732-11750. doi: 10.1021/acs.jmedchem.4c00269. Epub 2024 Jul 11. J Med Chem. 2024. PMID: 38991141
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: michaloglou c. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
11 results